SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN), a leading provider and developer of advanced personal telemedicine solutions, today announced that it has signed a distribution agreement for its innovative smartheart™ device with USCI Holdings, Inc., of Japan. USCI shall immediately order a sizable amount of smartheart™ devices already this quarter with a target of buying at least 1,000 smarthearts until the end of 2016.
smartheart™ is the first and only personal mobile 12-lead ECG device on the market that enables the detection of heart attacks. USCI Holdings will target the professional healthcare community, i.e. physicians and general practitioners. With smartheart and a smartphone or tablet they can perform a full hospital grade ECG and receive from SHL's global telemedicine centre an ECG interpretation.
Erez Alroy, Co-CEO of SHL, commented: "We are delighted to have signed this important distribution agreement in Japan with USCI. It is a validation for the unique features of our smartheart™ and allows SHL, with the focus on physicians and the professional market, to build credibility for the smartheart in the Japanese healthcare community."
Cirrhosis patients face mixed infection outcomes amid pandemic healthcare shifts